Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia

Avindra Nath, Carol Anderson, Melina Jones, William Maragos, Rosemarie Booze, Charles Mactutus, Jeanne Bell, Kurt Hauser, Mark Mattson

Research output: Contribution to journalArticle

Abstract

Infection with the human immunodefiency virus (HIV) selectively targets the basal ganglia resulting in loss of dopaminergic neurons. Although frequently asymptomatic, some patients may develop signs of dopamine deficiency de novo. Accordingly, they are highly susceptible to drugs that act on dopaminergic systems. Both neuroleptics and psychostimulants may exacerbate these symptoms. Experimental evidence suggests that viral proteins such as gp120 and Tat can cause toxicity to dopaminergic neurons, and this toxicity is synergistic with compounds such as methamphetamine and cocaine that also act on the dopaminergic system. In addition, other neurotransmitters that modulate dopaminergic function, such as glutamate and opioids, may also modify the susceptibility of the dopamine system to HIV. Therefore, a thorough understanding of the mechanisms that lead to this selective neurotoxicity of dopaminergic neurons would also likely lead to the development of therapeutic modalities for patients with HIV dementia.

Original languageEnglish (US)
Pages (from-to)222-227
Number of pages6
JournalJournal of Psychopharmacology
Volume14
Issue number3
StatePublished - 2000
Externally publishedYes

Fingerprint

Dopaminergic Neurons
Dementia
Acquired Immunodeficiency Syndrome
Viruses
Dopamine
Methamphetamine
Viral Proteins
Basal Ganglia
Cocaine
Opioid Analgesics
Antipsychotic Agents
Neurotransmitter Agents
Glutamic Acid
Infection
Pharmaceutical Preparations
Therapeutics

Keywords

  • AIDS
  • Basa ganglia
  • Brain
  • Cocaine
  • Dementia
  • Dopamine
  • HIV
  • Methamphetamine
  • Neuroleptics
  • Opia tes
  • Parkinson's disease

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Nath, A., Anderson, C., Jones, M., Maragos, W., Booze, R., Mactutus, C., ... Mattson, M. (2000). Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. Journal of Psychopharmacology, 14(3), 222-227.

Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. / Nath, Avindra; Anderson, Carol; Jones, Melina; Maragos, William; Booze, Rosemarie; Mactutus, Charles; Bell, Jeanne; Hauser, Kurt; Mattson, Mark.

In: Journal of Psychopharmacology, Vol. 14, No. 3, 2000, p. 222-227.

Research output: Contribution to journalArticle

Nath, A, Anderson, C, Jones, M, Maragos, W, Booze, R, Mactutus, C, Bell, J, Hauser, K & Mattson, M 2000, 'Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia', Journal of Psychopharmacology, vol. 14, no. 3, pp. 222-227.
Nath A, Anderson C, Jones M, Maragos W, Booze R, Mactutus C et al. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. Journal of Psychopharmacology. 2000;14(3):222-227.
Nath, Avindra ; Anderson, Carol ; Jones, Melina ; Maragos, William ; Booze, Rosemarie ; Mactutus, Charles ; Bell, Jeanne ; Hauser, Kurt ; Mattson, Mark. / Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. In: Journal of Psychopharmacology. 2000 ; Vol. 14, No. 3. pp. 222-227.
@article{5a2351cf0eea4301ad494d46e30d6a7c,
title = "Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia",
abstract = "Infection with the human immunodefiency virus (HIV) selectively targets the basal ganglia resulting in loss of dopaminergic neurons. Although frequently asymptomatic, some patients may develop signs of dopamine deficiency de novo. Accordingly, they are highly susceptible to drugs that act on dopaminergic systems. Both neuroleptics and psychostimulants may exacerbate these symptoms. Experimental evidence suggests that viral proteins such as gp120 and Tat can cause toxicity to dopaminergic neurons, and this toxicity is synergistic with compounds such as methamphetamine and cocaine that also act on the dopaminergic system. In addition, other neurotransmitters that modulate dopaminergic function, such as glutamate and opioids, may also modify the susceptibility of the dopamine system to HIV. Therefore, a thorough understanding of the mechanisms that lead to this selective neurotoxicity of dopaminergic neurons would also likely lead to the development of therapeutic modalities for patients with HIV dementia.",
keywords = "AIDS, Basa ganglia, Brain, Cocaine, Dementia, Dopamine, HIV, Methamphetamine, Neuroleptics, Opia tes, Parkinson's disease",
author = "Avindra Nath and Carol Anderson and Melina Jones and William Maragos and Rosemarie Booze and Charles Mactutus and Jeanne Bell and Kurt Hauser and Mark Mattson",
year = "2000",
language = "English (US)",
volume = "14",
pages = "222--227",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia

AU - Nath, Avindra

AU - Anderson, Carol

AU - Jones, Melina

AU - Maragos, William

AU - Booze, Rosemarie

AU - Mactutus, Charles

AU - Bell, Jeanne

AU - Hauser, Kurt

AU - Mattson, Mark

PY - 2000

Y1 - 2000

N2 - Infection with the human immunodefiency virus (HIV) selectively targets the basal ganglia resulting in loss of dopaminergic neurons. Although frequently asymptomatic, some patients may develop signs of dopamine deficiency de novo. Accordingly, they are highly susceptible to drugs that act on dopaminergic systems. Both neuroleptics and psychostimulants may exacerbate these symptoms. Experimental evidence suggests that viral proteins such as gp120 and Tat can cause toxicity to dopaminergic neurons, and this toxicity is synergistic with compounds such as methamphetamine and cocaine that also act on the dopaminergic system. In addition, other neurotransmitters that modulate dopaminergic function, such as glutamate and opioids, may also modify the susceptibility of the dopamine system to HIV. Therefore, a thorough understanding of the mechanisms that lead to this selective neurotoxicity of dopaminergic neurons would also likely lead to the development of therapeutic modalities for patients with HIV dementia.

AB - Infection with the human immunodefiency virus (HIV) selectively targets the basal ganglia resulting in loss of dopaminergic neurons. Although frequently asymptomatic, some patients may develop signs of dopamine deficiency de novo. Accordingly, they are highly susceptible to drugs that act on dopaminergic systems. Both neuroleptics and psychostimulants may exacerbate these symptoms. Experimental evidence suggests that viral proteins such as gp120 and Tat can cause toxicity to dopaminergic neurons, and this toxicity is synergistic with compounds such as methamphetamine and cocaine that also act on the dopaminergic system. In addition, other neurotransmitters that modulate dopaminergic function, such as glutamate and opioids, may also modify the susceptibility of the dopamine system to HIV. Therefore, a thorough understanding of the mechanisms that lead to this selective neurotoxicity of dopaminergic neurons would also likely lead to the development of therapeutic modalities for patients with HIV dementia.

KW - AIDS

KW - Basa ganglia

KW - Brain

KW - Cocaine

KW - Dementia

KW - Dopamine

KW - HIV

KW - Methamphetamine

KW - Neuroleptics

KW - Opia tes

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0033746611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033746611&partnerID=8YFLogxK

M3 - Article

C2 - 11106300

AN - SCOPUS:0033746611

VL - 14

SP - 222

EP - 227

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 3

ER -